CBT/SSRI

PreclinicalSmall molecule

BBaker Heart Research Institute

CBT/SSRI is one of 32 small molecule programs targeting Panic Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Panic DisorderActive, not recruiting

Panic DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Panic Disorder

#DrugCompanyPhaseTrials

Atarax

Pfizer

Approved

1 2

Paxil CR

GSK

Approved

1 3

Brintellix

Takeda

Approved

1 4

Cymbalta

Alnylam Pharmaceuticals

Approved

1 5

Paxil

SSebela Pharmaceuticals Development LLC

Approved

6 6

Lexapro

AbbVie

Approved

—7

Xanax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 8

Celexa

AbbVie

Approved

—9

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

2 10

Zoloft

VViatris Specialty LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Panic Disorder1 trial

Panic Disorder and Cardiac Risk

Unknown status·—·N/A·NCT00168506·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CBT/SSRI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBT/SSRI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBT/SSRI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baker Heart Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBaker Heart Research Institute

CBT/SSRI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Panic Disorder1 trial

References

Drug Info

Quick Facts

Related News